Alembic
99.78
-3.33(-3.23%)
Market Cap₹2,562.20 Cr
PE Ratio8.08
IndustryRealty
Company Performance:
1D-3.23%
1M-3.72%
6M+0.98%
1Y-28.30%
5Y-5.82%
View Company Insightsright
More news about Alembic
19Aug 25
Alembic Limited Seeks Shareholder Approval for Udit Amin's Appointment as Managing Director
Alembic Limited seeks shareholder approval for appointing Udit Amin as Managing Director for a five-year term starting October 1, 2025. The proposed remuneration package includes a maximum CTC of Rs. 10.00 crore per annum. Amin, with over 22 years of industry experience, is currently a Non-Executive Non-Independent Director. The appointment requires shareholder approval through e-voting and Central Government approval due to Amin's NRI status. Current Managing Director & CEO, Mrs. Malika Amin, will step down and transition to a Non-Executive role.
19Aug 25
Glenmark Pharmaceuticals Among Three Indian Firms Recalling Products in US Market
Alembic Pharmaceuticals, Glenmark Pharmaceuticals, and Sun Pharmaceutical Industries are recalling multiple products from the US market due to manufacturing defects. Glenmark is recalling 73,056 units of Carvedilol Tablets and 22,656 bottles of Theophylline Extended-Release Tablets. Alembic is recalling 9,492 bottles of Doxepin Hydrochloride capsules, while Sun Pharma's US arm is recalling 11,328 bottles of Spironolactone tablets. The recalls, classified as Class II by the FDA, are due to issues such as nitrosamine impurity levels and contamination with aluminum.
16Aug 25
Alembic Pharma Secures USFDA Approval for Tretinoin Cream 0.025%
Alembic Pharmaceuticals has received final approval from the USFDA for Tretinoin Cream 0.025%, a topical medication used in dermatology. This approval allows the company to market and distribute the product in the United States, potentially expanding its dermatological portfolio and strengthening its position in the U.S. pharmaceutical market. The approval is expected to contribute to revenue growth and enhance Alembic's market presence.
12Aug 25
Alembic Reports Q1 Profit Growth Amid Revenue Dip; Announces Leadership Changes
Alembic Limited's Q1 consolidated net profit increased by 2.30% to ₹178.00 crore, while revenue declined by 2.17% to ₹497.00 crore. EBITDA decreased to ₹196.00 crore with a margin of 39.44%. The API segment showed growth with revenue of ₹129.50 crore, while the Real Estate segment declined to ₹368.00 crore. The company announced leadership changes with Mr. Udit Amin appointed as Managing Director effective October 1, 2025, and Mrs. Malika Amin resigning as MD & CEO effective January 1, 2026.
05Aug 25
Alembic Pharma Reports 15% Jump in Q1 Net Profit, Revenue Grows 10%
Alembic Pharmaceuticals posted robust Q1 FY24 results. Net profit increased by 15% to ₹154.00 crore, while revenue grew 10% to ₹1,711.00 crore year-on-year. EBITDA rose 19% to ₹282.00 crore, with EBITDA margin expanding by 130 bps to 16.50%. Despite positive financials, the company's stock traded flat at ₹968.75, with an 8% year-to-date decline.
26Jul 25
Alembic Pharma Secures USFDA Approval for Carbamazepine Extended Release Tablets
Alembic Pharmaceuticals received final USFDA approval for Carbamazepine extended release tablets in 100mg, 200mg, and 400mg strengths. The drug, equivalent to Novartis' Tegretol-XR, is used as an anti-convulsant and for treating trigeminal neuralgia pain. The estimated market size for these tablets is $71.00 million for the 12 months ending March 2025. This approval brings Alembic's total ANDA approvals to 225, including 202 final and 23 tentative approvals. Despite the news, Alembic's shares closed 1.91% lower at ₹999.00.
13May 25
Alembic Reports Q4 Profit Growth and Announces Dividend
Alembic Pharmaceuticals has released its Q4 financial results, showing significant growth. Net profit increased by 11.8% to ₹238.00 crore, while revenue grew by 23% to ₹603.00 crore. EBITDA rose by 13% to ₹273.00 crore, although the EBITDA margin slightly decreased. The company's board has recommended a dividend of ₹2.40 per equity share.
Alembic
99.78
-3.33
(-3.23%)
1 Year Returns:-28.30%
Industry Peers
DLF
716.05
(-0.69%)
Lodha Developers
1,141.10
(-0.72%)
Godrej Properties
1,957.60
(-0.50%)
Oberoi Realty
1,577.70
(-1.39%)
Phoenix Mills
1,540.40
(-1.43%)
Anant Raj
679.70
(+0.28%)
Brigade Enterprises
905.10
(-1.67%)
Sobha
1,542.20
(-1.12%)
Signatureglobal
1,055.20
(-2.22%)